HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.

AbstractAIM:
The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). Eviprostat was used as a control to study the efficacy of naftopidil.
METHODS:
Forty-nine patients with BPH (mean age 67.9 +/- 7.8 years) were involved in the study. Patients were randomly assigned either to the naftopidil group, which was treated with the alpha-blocker naftopidil (50-75 mg daily, 36 patients), or the eviprostat group, which was treated with phytotherapy (six tablets of eviprostat daily, 13 patients).
RESULTS:
The mean total IPSS, the total storage and voiding symptom scores, and the quality of life score decreased significantly (P < 0.0001 for each variable) in the naftopidil group, but not in the eviprostat group. In the naftopidil group, analyses showed significant increases in average and maximum flow rate and bladder capacity at first desire to void (P < 0.001, P = 0.001 and P = 0.024, respectively), and significant decreases in the postvoid residual, the percent of residual and the Abrams-Griffiths number (P = 0.009, P = 0.008 and P = 0.042, respectively). However, in the eviprostat group, no significant changes were noted in terms of these symptomatic and urodynamic parameters. In the pressure/flow study, an improvement in the International Continence Society nomogram grade was noted in 29% of the naftopidil group, but in only 16% of the eviprostat group. Among the 14 patients in the naftopidil group, detrusor overactivity disappeared in 21% and cystometric capacity increased in 36%, but no improvement in detrusor overactivity was noted in the eviprostat group.
CONCLUSIONS:
Naftopidil appears to have been effective in this short-term treatment of BPH.
AuthorsTomonori Yamanishi, Kosaku Yasuda, Takao Kamai, Toshihiko Tsujii, Ryuji Sakakibara, Tomoyuki Uchiyama, Ken-Ichiro Yoshida
JournalInternational journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 11 Issue 7 Pg. 501-9 (Jul 2004) ISSN: 0919-8172 [Print] Australia
PMID15242359 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic alpha-Antagonists
  • Drug Combinations
  • Naphthalenes
  • Piperazines
  • Plant Extracts
  • Plant Preparations
  • Ethamsylate
  • eviprostat
  • naftopidil
Topics
  • Adrenergic alpha-Antagonists (therapeutic use)
  • Aged
  • Drug Combinations
  • Ethamsylate (therapeutic use)
  • Humans
  • Male
  • Naphthalenes (therapeutic use)
  • Phytotherapy
  • Piperazines (therapeutic use)
  • Plant Extracts (therapeutic use)
  • Plant Preparations (therapeutic use)
  • Prostatic Hyperplasia (drug therapy, physiopathology)
  • Single-Blind Method
  • Urodynamics (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: